4,100 Shares in Astera Labs, Inc. $ALAB Bought by Trilogy Capital Inc.

Key Points

• Trilogy Capital Inc. purchased 4,100 shares of Astera Labs, Inc. for about $371,000 during the second quarter, signaling significant institutional interest in the company's stock.
• Insider activity showed that Director Jack R. Lazar sold 22,500 shares for approximately $4 million, reducing his position by 18.77%, while General Counsel Philip Mazzara sold 10,000 shares valued at about $1.9 million.
• Astera Labs' recent earnings report revealed a 149.5% increase in revenue year-over-year, with earnings per share beating analysts' estimates.

Trilogy Capital Inc. bought a new position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 4,100 shares of the company's stock, valued at approximately $371,000.

A number of other large investors also recently added to or reduced their stakes in the business. Pacific Point Advisors LLC raised its position in Astera Labs by 42.9% in the 2nd quarter. Pacific Point Advisors LLC now owns 10,000 shares of the company's stock worth $904,000 after purchasing an additional 3,000 shares during the period. PFG Investments LLC purchased a new position in Astera Labs in the 2nd quarter worth $238,000. Janney Montgomery Scott LLC purchased a new position in Astera Labs in the 2nd quarter worth $559,000. GC Wealth Management RIA LLC purchased a new position in Astera Labs in the 2nd quarter worth $318,000. Finally, Sound Income Strategies LLC raised its position in Astera Labs by 31.1% in the 2nd quarter. Sound Income Strategies LLC now owns 1,038 shares of the company's stock worth $94,000 after purchasing an additional 246 shares during the period. Hedge funds and other institutional investors own 60.47% of the company's stock.

Insider Activity

In other news, Director Jack R. Lazar sold 22,500 shares of Astera Labs stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $178.42, for a total transaction of $4,014,450.00. Following the sale, the director owned 97,351 shares of the company's stock, valued at approximately $17,369,365.42. The trade was a 18.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $188.70, for a total transaction of $1,887,000.00. Following the sale, the general counsel directly owned 161,573 shares in the company, valued at $30,488,825.10. The trade was a 5.83% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,482,036 shares of company stock worth $230,685,952. 12.50% of the stock is owned by company insiders.

Astera Labs Trading Down 0.7%

Shares of ALAB opened at $194.50 on Thursday. The firm's 50-day moving average price is $186.50 and its 200-day moving average price is $117.29. The firm has a market capitalization of $32.33 billion, a price-to-earnings ratio of 347.32, a PEG ratio of 4.97 and a beta of 1.43. Astera Labs, Inc. has a 1-year low of $47.13 and a 1-year high of $262.90.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.11. The firm had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The company's revenue for the quarter was up 149.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, research analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on ALAB. Barclays restated an "overweight" rating and issued a $155.00 price objective (up previously from $75.00) on shares of Astera Labs in a research report on Thursday, August 7th. TD Cowen began coverage on shares of Astera Labs in a research report on Wednesday. They issued a "hold" rating and a $200.00 price objective on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Astera Labs from $160.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Citigroup boosted their price objective on shares of Astera Labs from $160.00 to $275.00 and gave the company a "buy" rating in a research report on Wednesday, September 17th. Finally, Evercore ISI boosted their price objective on shares of Astera Labs from $104.00 to $215.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $155.71.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.